EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY-NC 4.0

Population Pharmacokinetics and Pharmacodynamics of Immunoglobulins: A Systematic Review

S L van der Zeeuw iD, S J van Tilburg iD, B C Jacobs iD, B C P Koch iD, V A S H Dalm iD, M B S Crombag iD, T Preijers iD

Clinical Pharmacokinetics · 2026-06 · 65 (6) · 811-836

DOI: 10.1007/s40262-026-01641-5 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Clinical Pharmacokinetics, online erschienen am 26.05.2026. Verfasst von S L van der Zeeuw und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hospital Pharmacy, Erasmus MC, Erasmus University Medical Center Rotterdam, Dr Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Immunoglobulins, Intravenous, Models, Biological, Immunoglobulin G, Immunologic Deficiency Syndromes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVE: Intravenous and/or subcutaneous immunoglobulins (IVIg/SCIg) are used as immunoglobulin replacement therapy (IgRT) in primary and secondary immunodeficiencies (PID/SID) and as immunomodulatory therapy in immune-mediated diseases. Despite empiric immunoglobulin G (IgG) target concentrations in PID, dosing remains variable and suboptimal, particularly in immune-mediated diseases lacking clear IgG target concentrations. Population pharmacokinetic (popPK) and pharmacodynamic (PD) modelling may clarify interindividual variability and support individualised dosing. Recent developments extend beyond PID, emphasising the importance of integrated PK-PD approaches to optimise IgG therapy. This review aimed to provide a comprehensive overview of popPK(-PD) models describing polyclonal IgG therapy, and to emphasise the added value of PK-PD in understanding drug behaviour. METHODS: A systematic literature search was conducted in Embase, MEDLINE, and Web of Science from inception to August 2025. Studies describing popPK(-PD) models for exogenous polyclonal IVIg and/or SCIg administration in humans were included. RESULTS: In total, 14 studies were included. While most popPK models focus on PID (N = 10), an increasing number address immune-mediated diseases. Immunoglobulin G pharmacokinetics are typically described using two-compartment models with first-order kinetics, using body weight (BW) as a common covariate for clearance and volume of distribution. Endogenous IgG is often incorporated as a fixed PK parameter; however, this may not adequately capture interindividual variability and potential effects of Ig treatment on IgG concentrations. Two popPK-PD models link IgG concentrations to clinical outcomes in immune-mediated diseases. In contrast, such models are currently lacking for PID. Simulations showed consistent predicted IgG concentrations following SCIg in PID, while IVIg models in PID showed more variability. CONCLUSIONS: PopPK models have advanced understanding of IgG PK and its variability between patients and treatment regimens. These models provide a powerful framework to support individualised dosing strategies, thereby potentially reducing reliance on empirical, trial-and-error dosing approaches. However, clear target concentrations are lacking and must be established for individual patients. Models may be further optimised by incorporating essential Neonatal Fc receptor (FcRn) mechanisms using physiology-based pharmacokinetic (PBPK) or semi-mechanistic models. In conclusion, current models are useful to predict IgG concentrations across diseases during Ig treatment; however, a clearer relationship with PD is required. Hence, these findings can guide clinical trial design for tailored dosing regimens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunoglobulins, IntravenousModels, BiologicalImmunoglobulin GImmunologic Deficiency SyndromesHumans

Substanzen

Immunoglobulins, IntravenousImmunoglobulin G

Autor:innen und Institutionen

  • Department of Hospital Pharmacy, Erasmus MC, Erasmus University Medical Center Rotterdam, Dr Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands.
  • Rotterdam Clinical Pharmacometrics Group, Rotterdam, The Netherlands.
  • Department of Immunology, Erasmus MC, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands.
  • Department of Neurology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.
  • Department of Internal Medicine, Division of Allergy and Clinical Immunology, Erasmus MC, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands.
  • Department of Hospital Pharmacy, Erasmus MC, Erasmus University Medical Center Rotterdam, Dr Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands. t.preijers@erasmusmc.nl.

ORCID-Profile: S L van der Zeeuw, S J van Tilburg, B C Jacobs, B C P Koch, V A S H Dalm, M B S Crombag, T Preijers

Zitieren

APA

van der Zeeuw, S. L., van Tilburg, S. J., Jacobs, B. C., Koch, B. C. P., Dalm, V. A. S. H., Crombag, M. B. S., & Preijers, T. (2026). Population Pharmacokinetics and Pharmacodynamics of Immunoglobulins: A Systematic Review. Clinical Pharmacokinetics, 65(6), 811-836. https://doi.org/10.1007/s40262-026-01641-5

Vancouver

van der Zeeuw SL, van Tilburg SJ, Jacobs BC, Koch BCP, Dalm VASH, Crombag MBS, et al. Population Pharmacokinetics and Pharmacodynamics of Immunoglobulins: A Systematic Review. Clinical Pharmacokinetics. 2026;65(6):811-836. doi:10.1007/s40262-026-01641-5

BibTeX
@article{vanderZeeuw2026,
  author = {van der Zeeuw, S L and van Tilburg, S J and Jacobs, B C and Koch, B C P and Dalm, V A S H and Crombag, M B S and Preijers, T},
  title = {Population Pharmacokinetics and Pharmacodynamics of Immunoglobulins: A Systematic Review},
  journal = {Clinical Pharmacokinetics},
  year = {2026},
  volume = {65},
  number = {6},
  pages = {811--836},
  doi = {10.1007/s40262-026-01641-5}
}
Kostenlos starten →